S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
NASDAQ:NVAX

Novavax (NVAX) Stock Price, News & Analysis

$4.28
-0.02 (-0.47%)
(As of 04/12/2024 ET)
Today's Range
$4.24
$4.48
50-Day Range
$3.76
$6.02
52-Week Range
$3.53
$11.36
Volume
4.01 million shs
Average Volume
4.03 million shs
Market Capitalization
$598.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Novavax MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
297.2% Upside
$17.00 Price Target
Short Interest
Healthy
31.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.32mentions of Novavax in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.88) to $0.08 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.90 out of 5 stars

Medical Sector

204th out of 927 stocks

Biological Products, Except Diagnostic Industry

24th out of 157 stocks

NVAX stock logo

About Novavax Stock (NASDAQ:NVAX)

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

NVAX Stock Price History

NVAX Stock News Headlines

The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (NVAX)
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Novavax (NASDAQ:NVAX) Trading 3.5% Higher
Better Buy: Bluebird Bio Vs. Novavax
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
NVAX Mar 2024 8.000 call
(NVAX) - Analyzing Novavax's Short Interest
NVAX Mar 2024 8.500 put
Novavax, Inc. Common Stock (NVAX)
NVAX Mar 2024 9.000 put
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/14/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,543
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$19.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+297.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-545,060,000.00
Pretax Margin
-55.20%

Debt

Sales & Book Value

Annual Sales
$983.71 million
Book Value
($6.04) per share

Miscellaneous

Free Float
138,693,000
Market Cap
$598.99 million
Optionable
Optionable
Beta
1.59

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. John Joseph Trizzino B.S. (Age 64)
    M.B.A., President & COO
    Comp: $641.22k
  • Mr. James Patrick Kelly C.F.A. (Age 58)
    Executive VP, CFO & Treasurer
    Comp: $644.32k
  • Mr. Stanley Charles Erck (Age 76)
    Advisor
    Comp: $1.09M
  • Mr. John Charles Jacobs M.B.A. (Age 57)
    CEO & Director
  • Mr. Richard P. Crowley (Age 67)
    Executive VP & COO
  • Mr. Troy Morgan Esq. (Age 53)
    J.D., Senior VP & Chief Compliance Officer
  • Mr. Mark Casey
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Erika S. Trahan
    Associate Director of Investor & Public Relations
  • Mr. Ian J. Watkins (Age 61)
    Executive VP & Chief Human Resources Officer
  • Ms. Silvia Taylor M.B.A.
    Executive VP and Chief Corporate Affairs & Advocacy Officer

NVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVAX shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price target for 2024?

3 Wall Street analysts have issued 12 month price objectives for Novavax's shares. Their NVAX share price targets range from $15.00 to $19.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 297.2% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2024?

Novavax's stock was trading at $4.80 at the beginning of 2024. Since then, NVAX stock has decreased by 10.8% and is now trading at $4.28.
View the best growth stocks for 2024 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.95. The biopharmaceutical company earned $291.34 million during the quarter, compared to the consensus estimate of $310.96 million. The business's revenue was down 18.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.28) earnings per share.

When did Novavax's stock split?

Shares of Novavax reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $800.0 million-$1.0 billion, compared to the consensus revenue estimate of $969.6 million.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include IMC Chicago LLC (0.00%). Insiders that own company stock include David M Mott, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVAX) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners